GlassScriptPhysician profile
Krystalyn Williams
NPI 1811740327
$2,946.06
in general payments reported to CMS, 2019-2025
15 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,036 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.96 |
| Education | $237.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $835.45 | 2024-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $422.58 | 2024-2025 | |
| Travere Therapeutics, INC. | $380.04 | 2024-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $257.56 | 2024-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $254.54 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $234.02 | 2024-2025 | Rayaldee |
| Ardelyx, INC. | $121.62 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $120.84 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $108.23 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.97 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $53.50 | 2024-2025 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $33.08 | 2024-2025 | Gattex |
| Shield Therapeutics INC | $21.34 | 2024 | |
| Akebia Therapeutics INC | $18.74 | 2025 | Vafseo |
| Scpharmaceuticals INC. | $18.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystalyn Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.